Lots of investors new to OTC stocks got burnt by the blatant short manipulation and are out until further notice. Hence the fall off in volume. It'll come back when we have indisputable news of the efficacy of leronlimab. A peek into s/c may not do it, though I expect a rise from the results of it. FDA EUA for use for s/c will do it.